Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Deciphera Pharmaceuticals stock | $34.83

Learn how to easily invest in Deciphera Pharmaceuticals stock.

Deciphera Pharmaceuticals Inc is a biotechnology business based in the US. Deciphera Pharmaceuticals shares (DCPH) are listed on the NASDAQ and all prices are listed in US Dollars. Deciphera Pharmaceuticals employs 350 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Deciphera Pharmaceuticals

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – DCPH – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Deciphera Pharmaceuticals stock price (NASDAQ: DCPH)

Use our graph to track the performance of DCPH stocks over time.

Deciphera Pharmaceuticals shares at a glance

Information last updated 2021-10-10.
Latest market close$34.83
52-week range$26.20 - $66.64
50-day moving average $32.01
200-day moving average $35.50
Wall St. target price$64.55
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-4.50

Buy Deciphera Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Deciphera Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Deciphera Pharmaceuticals price performance over time

Historical closes compared with the close of $34.83 from 2021-10-15

1 week (2021-10-08) 7.77%
1 month (2021-09-17) 5.61%
3 months (2021-07-16) 2.26%
6 months (2021-04-16) -25.89%
1 year (2020-10-16) -40.88%
2 years (2019-10-17) 2.26%
3 years (2018-10-17) 21.57%
5 years (2016-10-13) N/A

Deciphera Pharmaceuticals financials

Revenue TTM $83.7 million
Gross profit TTM $-157,108,000
Return on assets TTM -26.39%
Return on equity TTM -48.42%
Profit margin 0%
Book value $7.70
Market capitalisation $1.9 billion

TTM: trailing 12 months

Shorting Deciphera Pharmaceuticals shares

There are currently 2.6 million Deciphera Pharmaceuticals shares held short by investors – that's known as Deciphera Pharmaceuticals's "short interest". This figure is 7.4% down from 2.8 million last month.

There are a few different ways that this level of interest in shorting Deciphera Pharmaceuticals shares can be evaluated.

Deciphera Pharmaceuticals's "short interest ratio" (SIR)

Deciphera Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Deciphera Pharmaceuticals shares currently shorted divided by the average quantity of Deciphera Pharmaceuticals shares traded daily (recently around 364977.73049645). Deciphera Pharmaceuticals's SIR currently stands at 7.05. In other words for every 100,000 Deciphera Pharmaceuticals shares traded daily on the market, roughly 7050 shares are currently held short.

However Deciphera Pharmaceuticals's short interest can also be evaluated against the total number of Deciphera Pharmaceuticals shares, or, against the total number of tradable Deciphera Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Deciphera Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Deciphera Pharmaceuticals shares in existence, roughly 40 shares are currently held short) or 0.0767% of the tradable shares (for every 100,000 tradable Deciphera Pharmaceuticals shares, roughly 77 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Deciphera Pharmaceuticals.

Find out more about how you can short Deciphera Pharmaceuticals stock.

Deciphera Pharmaceuticals share dividends

We're not expecting Deciphera Pharmaceuticals to pay a dividend over the next 12 months.

Deciphera Pharmaceuticals share price volatility

Over the last 12 months, Deciphera Pharmaceuticals's shares have ranged in value from as little as $26.2 up to $66.64. A popular way to gauge a stock's volatility is its "beta".

DCPH.US volatility(beta: 1.41)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Deciphera Pharmaceuticals's is 1.4122. This would suggest that Deciphera Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Deciphera Pharmaceuticals overview

Deciphera Pharmaceuticals, Inc. , a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing immunokinase inhibitors comprising vimseltinib (DCC-3014) that is in Phase 1b/2 clinical trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase 1b/2 clinical trial to treat metastatic solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, it is developing DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. The company serves in the United States and Europe. Deciphera Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Deciphera Pharmaceuticals is owned by insiders or institutions?
Currently 29.377% of Deciphera Pharmaceuticals shares are held by insiders and 77.002% by institutions.
How many people work for Deciphera Pharmaceuticals?
Latest data suggests 350 work at Deciphera Pharmaceuticals.
When does the fiscal year end for Deciphera Pharmaceuticals?
Deciphera Pharmaceuticals's fiscal year ends in December.
Where is Deciphera Pharmaceuticals based?
Deciphera Pharmaceuticals's address is: 200 Smith Street, Waltham, MA, United States, 02451
What is Deciphera Pharmaceuticals's ISIN number?
Deciphera Pharmaceuticals's international securities identification number is: US24344T1016
What is Deciphera Pharmaceuticals's CUSIP number?
Deciphera Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 24344T101

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site